Epidemiology of myasthenia gravis in Ontario, Canada

Breiner, Ari; Widdifield, Jessica; Katzberg, Hans D.; Barnett, Carolina; Bril, Vera; Tu, Karen

doi:10.1016/j.nmd.2015.10.009

Cited by 109 publications

(93 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The average values of crude MG incidence in Slovakia and the increase of MG occurrence in the higher age groups (70–99) are consistent with the findings of other authors [8-13]. …”

Section: Discussionsupporting

confidence: 91%

“…Only Breiner et al[8] referred higher crude prevalence (32.0/100,000) in Ontario, Canada in year 2013. The high MG prevalence in Slovakia reflects the (1) overall rise of mean life-expectancy in whole Slovak population due to improvements in healthcare generally, (2) centralization of MG management with quick MG diagnostics, early start of adequate immunotherapy and intensive follow up of MG patients resulting in good surviving of MG patients, and (3) gradual and significant increase of MG incidence during the study period.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology of Myasthenia Gravis in Slovakia in the Years 1977–2015

et al. 2018

View full text Add to dashboard Cite

Purpose: The objective of the study was to evaluate changes of epidemiological parameters in patients with myasthenia gravis (MG) in Slovakia during the period 1977–2015. Methods: Data from medical records of MG patients registered in Slovakia were analyzed. Epidemiological rates (incidence, prevalence, mortality) were assessed for several periods to identify changes and drifts over the period of study. Results: Out of 2,074 patients, 892 were males (43.0%) and 1,193 were females (57.0%). The thymoma associated MG (TAMG) was diagnosed in 123 patients (5.9%). The mean age at onset shifted from 35.8 years in 1977–1989 to 60.0 years in 2010–2015. The crude incidence increased from 0.36/100,000 in 1977–1989 to 1.74/100,000 in 2010–2015. The average annual incidence of TAMG was 0.05/100,000. Maximum increase of MG incidence was registered among the elderly (≥50 years), particularly in the group of patients in the age range 70–79 years (0.34/100,000 in 1977–1989→7.10/100,000 in 2010–2015) and 80–89 years (0.00/100,000 in 1977–1989→5.31/100,000 in 2010–2015). The crude MG prevalence on December 31, 2015 was 24.75/100,000. The average MG mortality was 0.27/100,000. Conclusion: The age at onset and incidence increased significantly over the study period due to marked increase of MG incidence in elderly, particularly over 70 years. Possible reasons for this trend are discussed.

show abstract

“…The average values of crude MG incidence in Slovakia and the increase of MG occurrence in the higher age groups (70–99) are consistent with the findings of other authors [8-13]. …”

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Epidemiology of Myasthenia Gravis in Slovakia in the Years 1977–2015

et al. 2018

View full text Add to dashboard Cite

show abstract

“…населения [3,5,9,10,[12][13][14][15]. Например, в Италии за последние 20 лет отмечен рост заболеваемости ми-астенией с 6,2 до 11,1 на 100 тыс.…”

Section: том 7 Volunclassified

Epidemiological and clinical characteristics of myasthenia in the Krasnoyarsk region

Gasymly¹,

Исаева²,

Прокопенко³

et al. 2017

Neuromuscular Diseases

View full text Add to dashboard Cite

“…Prosečna godišnja prevalencija za navedeno razdoblje iznosi 153,6/1.000.000 stanovnika. U svetu se vrednosti standardizovane prevalencije kreću od 27,7/1.000.000 do 354,7/1.000.000 stanovnika (13)(14)(15)(16)(17). Ovakav raspon vrednosti prevalencije mogao bi da se objasni razlikama u dijagnostičkim i terapijskim mogućnostima među zemljama.…”

Section: Diskusijaunclassified

“…MedPodml 2017, 68(1): [14][15][16][17][18][19][20] Uvod Stečena autoimuna miastenija gravis (MG) predstavlja autoimuno oboljenje u kome se javljaju antitela na različite postsinaptičke strukture neuromišićne spojnice, uglavnom na nikotinski acetilholinski receptor (nAChR), ali i na mišićno specifičnu tirozin kinazu (MuSK), protein 4 povezan sa lipoproteinom (LRP4) ili arginin (1). Ova antitela uzrokuju oštećenje neuromišićne transmisije i klinički dovode do mišićne slabosti i patološke zamorljivosti.…”

unclassified

Frequency of familial occurrence and associated autoimmune diseases in a cohort of patients with acquired autoimmune myasthenia gravis from Belgrade

Josipovic¹,

Jovanović²,

Jadžić³

et al. 2017

Med podmladak

View full text Add to dashboard Cite

Introduction: Myasthenia gravis (MG) can be associated with other autoimmune diseases (AID), most frequently with Hashimoto's thyroiditis, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Familial occurrence (FOMG) is rare and it exists in 3.5-4.2% patients with MG. Aim: To determine the occurrence of FOMG, the occurrence of AID associated with MG and to identify potential risk factors for developing MG in a cohort of patients from Belgrade. Material and Methods: This study gathered data from 453 patient histories from the period from1992-2014, from the Clinic of Neurology, Clinical Center of Serbia. Three analyses were performed. The first one measured the frequency of associated AID in patients with MG. In the second one, patients who had MG associated with AID were compared to patients without associated AID. The third one included patients with FOMG and compared them with patients without FOMG. The demographic and clinical characteristics of these patients were analysed and comparisons were made between observed and control groups. Results: The associated AID were present in 54 (11.9%) patients, the most frequent was Hashimoto thyreoiditis (4%), then SLE (1.3%), and RA, polymyositis and pernicious anaemia (0.9%). Patients with co-occurrence of MG and other AID were, in comparison with control group, more often female, and the difference was on the border of statistical significance (p=0.056). They had late onset MG (LOMG) more frequently, a mild form of MG and positive anti-AChR antibodies, but these differences weren't statistically significant. FOMG was seen in 2.2% of patients. They had LOMG more frequently, were predominantly men, seropositive, and with mild form of the disease, but with no statistical significance compared to the control group. Conclusion: In the Belgrade cohort, MG was often associated with other AID, while FOMG was relatively rare. There was no significant difference, statistically, in the observed clinical and demographic characteristics of analysed groups, compared to control groups.

show abstract

Epidemiology of myasthenia gravis in Ontario, Canada

Cited by 109 publications

References 14 publications

Epidemiology of Myasthenia Gravis in Slovakia in the Years 1977–2015

Epidemiology of Myasthenia Gravis in Slovakia in the Years 1977–2015

Epidemiological and clinical characteristics of myasthenia in the Krasnoyarsk region

Frequency of familial occurrence and associated autoimmune diseases in a cohort of patients with acquired autoimmune myasthenia gravis from Belgrade

Contact Info

Product

Resources

About